The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji

• Egile Nagusiak: R. Reyburn (Egilea), E.J. Tuivaga (Egilea), F.T. Ratu (Egilea), E.M. Dunne (Egilea), D. Nand (Egilea), J. Kado (Egilea), K. Jenkins (Egilea), L. Tikoduadua (Egilea), A. Jenney (Egilea), B.P. Howden (Egilea), S.A. Ballard (Egilea), K. Fox (Egilea), R. Devi (Egilea), C. Satzke (Egilea), E. Rafai (Egilea), M. Kama (Egilea), S. Flasche (Egilea), E.K. Mulholland (Egilea), F.M. Russell (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2022-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Summary: Background: In 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction. Methods: Laboratory-con...